Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Chaetocin Anti-Leukemia Activity Against Chronic Myelogenous Leukemia Stem Cells Is Potentiated By Bone Marrow Stromal Factors and Overcomes Innate Imatinib Resistance

Luke Truitt, PhD, Catherine Hutchinson, MSc, Karen Mochoruk, MLT, John F. DeCoteau, MD, C. Ronald Geyer, PhD

Blood (2014) 124 (21): 4517.

https://doi.org/10.1182/blood.V124.21.4517.4517

Published: 2014

Journal Articles

Synthetic Anti-IL3 Receptor Antibodies As Therapeutics to Block Innate Imatinib Resistance in Chronic Myelogenous Leukemia

Mahsa Abrishami, MSc, Landon Pastushok, PhD, Karen Mochoruk, MLT, John F. DeCoteau, MD, C. Ronald Geyer, PhD

Blood (2014) 124 (21): 4519.

https://doi.org/10.1182/blood.V124.21.4519.4519

Published: 2014

Journal Articles

Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells

Catherine Hutchinson, David P. Sheridan, MD, John F. DeCoteau, MD, Ron Geyer, PhD

Blood (2012) 120 (21): 1667.

https://doi.org/10.1182/blood.V120.21.1667.1667

Published: 2012

Journal Articles

Genetic Screen to Isolate “Lariat” Peptides for Characterizing ABL Kinase Activity and Conformation

V.M. Bharathikumar, Kris Barreto, Marciano D. Reis, MD, John F. Decoteau, MD, C. Ronald Geyer

Blood (2010) 116 (21): 438.

https://doi.org/10.1182/blood.V116.21.438.438

Published: 2010

Journal Articles

Stromal Cell-Derived Secreted Factors Contribute to the Innate Imatinib Resistance of Leukemia Stem Cells In a Genetically Defined Murine Model of Chronic Myeloid Leukemia Blast Crisis

C. Ronald Geyer, Michael Szeto, Ashton Craven, Marciano D. Reis, David P. Sheridan, John F. DeCoteau

Blood (2010) 116 (21): 204.

https://doi.org/10.1182/blood.V116.21.204.204

Published: 2010

Journal Articles

GNF-2, An Allosteric BCR-ABL Inhibitor, Identifies a Novel Myristoylation-Mediated Mechanism Regulating the Ability of BCR-ABL to Activate HCK and IGF-1 Signaling.

Ron Geyer, PhD, Teodora Zlateva, PhD, Asha Lakshmikuttyamma, PhD, David P. Sheridan, MD, John F. DeCoteau, MD

Blood (2009) 114 (22): 40.

https://doi.org/10.1182/blood.V114.22.40.40

Published: 2009

Journal Articles

Decreased Expression of the Histone Methyltransferase SUV39H1 in AML Cells Reactivates Hypermethylated Tumor Suppressor p15INK4B in the Absence of Promoter Demethylation.

Ashakumary Lakshmikuttyamma, PhD, Stuart Scott, PhD, C. Ronald Geyer, PhD, John F. DeCoteau, MD

Blood (2007) 110 (11): 4150.

https://doi.org/10.1182/blood.V110.11.4150.4150

Published: 2007

Journal Articles

BCR-ABL Induces Autocrine IGF-1 Signaling.

Asha Kumarylakshmikuttyamma, PhD, Elodie Pastural, PhD, John F. DeCoteau, MD, C. Ronald Geyer, PhD

Blood (2007) 110 (11): 4545.

https://doi.org/10.1182/blood.V110.11.4545.4545

Published: 2007

Journal Articles

BCR-ABL Activates IGF-1 Expression and Signaling in Chronic Myelogenous Leukemia Blast Crisis Cell Lines.

Elodie Pastural, PhD, Ashakumary Lakshmikuttyamma, PhD, Naoto Takahashi, MD, PhD, Derek Pearson, MD, David Sheridan, MD, John F. DeCoteau, MD, C. Ronald Geyer, PhD

Blood (2006) 108 (11): 1932.

https://doi.org/10.1182/blood.V108.11.1932.1932

Published: 2006

Journal Articles

Identification of Target Genes for the Tumor Suppressor RIZ1 Using Gene Expression Profiling.

Wei-Feng Dong, MD, PhD, Naoto Takahashi, MD, PhD, Matthew N. Bainbridge, BSc, Andrea R. Hull, BSc, Stuart A. Scott, BSc, C. R. Geyer, PhD, John F. DeCoteau, MD

Blood (2004) 104 (11): 4351.

https://doi.org/10.1182/blood.V104.11.4351.4351

Published: 2004

Journal Articles

Identification of RIZ1 Targets Involvedin Erythroid Differentiation of K562 Human Erythroleukemia Cells Using Surface-Enhanced Laser Desorption Ionization Time-Of-Flight Mass Spectrometry (SELDI).

Naoto Takahashi, MD, PhD, Matthew Brainbridge, BSc, Stuart A. Scott, BSc, Ryo Ichinohasama, MD, PhD, Stephen E. Sanche, MD, Wei-Feng Dong, MD, PhD, John F. DeCoteau, MD, C. R. Geyer, PhD

Blood (2004) 104 (11): 2031.

https://doi.org/10.1182/blood.V104.11.2031.2031

Published: 2004

Journal Articles

cDNA Microarray Analysis of Genes Up-Regulated by Treatment with 5-AZA-2′-Deoxycytidine in Combination with Trichostatin A Identifies Aberrant Metallothionein 1H Promoter Methylation at a High Frequency Iin Human AML.

Stuart A. Scott, BSc, Derek S. Pearson, MD, Matthew N. Bainbridge, BSc, Wei-Feng Dong, MD, PhD, Naoto Takahashi, MD, PhD, David P. Sheridan, MD, Ryo Ichinohasama, MD, PhD, C. R. Geyer, PhD, John F. DeCoteau, MD

Blood (2004) 104 (11): 2036.

https://doi.org/10.1182/blood.V104.11.2036.2036

Published: 2004

Journal Articles

MSH2- deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability

Robert Lowsky, Anthony Magliocco, Ryo Ichinohasama, Armin Reitmair, Stuart Scott, Michele Henry, Marshall E. Kadin, John F. DeCoteau

Blood (2000) 95 (5): 1767–1772.

https://doi.org/10.1182/blood.V95.5.1767.005k07_1767_1772

Published: 2000

Journal Articles

Defects of the Mismatch Repair Gene MSH2 Are Implicated in the Development of Murine and Human Lymphoblastic Lymphomas and Are Associated With the Aberrant Expression of Rhombotin-2 (Lmo-2) and Tal-1 (SCL)

Robert Lowsky, John F. DeCoteau, Armin H. Reitmair, Ryo Ichinohasama, Wei-Feng Dong, Yi Xu, Tak W. Mak, Marshall E. Kadin, Mark D. Minden

Blood (1997) 89 (7): 2276–2282.

https://doi.org/10.1182/blood.V89.7.2276

Published: 1997

NARROW

Chaetocin Anti-Leukemia Activity Against Chronic Myelogenous Leukemia Stem Cells Is Potentiated By Bone Marrow Stromal Factors and Overcomes Innate Imatinib Resistance

Synthetic Anti-IL3 Receptor Antibodies As Therapeutics to Block Innate Imatinib Resistance in Chronic Myelogenous Leukemia

Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells

Genetic Screen to Isolate “Lariat” Peptides for Characterizing ABL Kinase Activity and Conformation

Stromal Cell-Derived Secreted Factors Contribute to the Innate Imatinib Resistance of Leukemia Stem Cells In a Genetically Defined Murine Model of Chronic Myeloid Leukemia Blast Crisis

GNF-2, An Allosteric BCR-ABL Inhibitor, Identifies a Novel Myristoylation-Mediated Mechanism Regulating the Ability of BCR-ABL to Activate HCK and IGF-1 Signaling.

Decreased Expression of the Histone Methyltransferase SUV39H1 in AML Cells Reactivates Hypermethylated Tumor Suppressor p15INK4B in the Absence of Promoter Demethylation.

BCR-ABL Induces Autocrine IGF-1 Signaling.

BCR-ABL Activates IGF-1 Expression and Signaling in Chronic Myelogenous Leukemia Blast Crisis Cell Lines.

Identification of Target Genes for the Tumor Suppressor RIZ1 Using Gene Expression Profiling.

Identification of RIZ1 Targets Involvedin Erythroid Differentiation of K562 Human Erythroleukemia Cells Using Surface-Enhanced Laser Desorption Ionization Time-Of-Flight Mass Spectrometry (SELDI).

cDNA Microarray Analysis of Genes Up-Regulated by Treatment with 5-AZA-2′-Deoxycytidine in Combination with Trichostatin A Identifies Aberrant Metallothionein 1H Promoter Methylation at a High Frequency Iin Human AML.

MSH2- deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability

Defects of the Mismatch Repair Gene MSH2 Are Implicated in the Development of Murine and Human Lymphoblastic Lymphomas and Are Associated With the Aberrant Expression of Rhombotin-2 (Lmo-2) and Tal-1 (SCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only